Skip to main content
. 2019 Oct 29;7(10):e2461. doi: 10.1097/GOX.0000000000002461

Table 4.

Comorbidities and Intraoperative Characteristics

Transfemale Augmentation Cisfemale Augmentation P
No. of patients 280 1,080
Mean BMI ± SD (kg/m2) 26.7 ± 5.6 22.3 ± 3.4 <0.001
 Nonobese (BMI ≤ 29.9 kg/m2) 206 (75.7%) 1,027 (96.8%) <0.001
 Obese (BMI ≥ 30.0 kg/m2) 66 (24.3%) 34 (3.2%)
ASA classification <0.001
 1. No disturbance 76 (27.1%) 663 (61.4%)
 2. Mild disturbance 184 (65.7%) 403 (37.3%)
 3. Severe disturbance 19 (6.8%) 14 (1.3%)
Location of procedure <0.001
 Inpatient 13 (4.6%) 6 (0.6%)
 Outpatient 267 (95.4%) 1074 (99.4%)
Smoking <0.001
 Yes 76 (27.1%) 118 (10.9%)
 No 204 (72.9%) 962 (89.1%)
Diabetes (type I or type II) 12 (4.3%) 10 (0.9%) <0.001
Hypertension 29 (10.4%) 34 (3.1%) <0.001
Steroid use 2 (0.7%) 1 (0.1%) 0.048
Operative time (min) 95.9 ± 69.1 75.5 ± 49.6 <0.001
Length of stay (d) 0.31 ± 1.4 0.11 ± 4.5 0.479

ASA, American Society of Anesthesiologists.